2 weeks Regeneron’s antibody drug added to UK Recovery trial of COVID treatments Inquirer
LONDON --- The world's largest randomized trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalized with the disease. The UK RECOVERY trial, which has been testing a range of potential COVID-19 treatments since it began in April, will compare the effects of adding REGN-COV2 - a lab-manufactured monoclonal antibody - to standard care. "This is the first drug actually designed for this disease," said Martin Landray, a professor of medicine & epidemiology at Oxford University who is co-leading the trial. "There are lots of good ... more